Omeros’ (OMER) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital restated their buy rating on shares of Omeros (NASDAQ:OMER) in a research note issued to investors on Thursday morning,Benzinga reports. They currently have a $36.00 price objective on the biopharmaceutical company’s stock.

Other equities research analysts have also issued reports about the company. Rodman & Renshaw initiated coverage on Omeros in a research report on Thursday, November 14th. They set a “buy” rating and a $9.00 price target on the stock. RODMAN&RENSHAW raised Omeros to a “strong-buy” rating in a research report on Thursday, November 14th. Needham & Company LLC reissued a “hold” rating on shares of Omeros in a research report on Friday, January 17th. StockNews.com raised Omeros from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Omeros in a research report on Thursday, November 14th. Three research analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $22.50.

Omeros Stock Performance

Shares of NASDAQ:OMER opened at $9.18 on Thursday. The stock has a market capitalization of $531.98 million, a P/E ratio of -3.97 and a beta of 1.98. The stock has a 50-day simple moving average of $9.30 and a 200-day simple moving average of $6.74. Omeros has a 1 year low of $2.61 and a 1 year high of $13.60.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of OMER. Truvestments Capital LLC boosted its stake in Omeros by 116.5% during the fourth quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 1,669 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in Omeros by 79.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company’s stock valued at $44,000 after buying an additional 1,972 shares in the last quarter. Quantbot Technologies LP bought a new position in Omeros during the fourth quarter valued at about $46,000. BNP Paribas Financial Markets boosted its stake in Omeros by 130.6% during the third quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock valued at $49,000 after buying an additional 7,016 shares in the last quarter. Finally, Picton Mahoney Asset Management boosted its stake in Omeros by 692.5% during the fourth quarter. Picton Mahoney Asset Management now owns 5,040 shares of the biopharmaceutical company’s stock valued at $50,000 after buying an additional 4,404 shares in the last quarter. Institutional investors own 48.79% of the company’s stock.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.